TIAA CREF Investment Management LLC reduced its holdings in shares of Humana Inc (NYSE:HUM) by 3.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,302,530 shares of the insurance provider’s stock after selling 42,654 shares during the quarter. TIAA CREF Investment Management LLC owned 0.95% of Humana worth $323,119,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. Wells Fargo & Company MN lifted its stake in Humana by 10.0% during the third quarter. Wells Fargo & Company MN now owns 1,653,318 shares of the insurance provider’s stock worth $402,799,000 after purchasing an additional 150,173 shares during the last quarter. Commonwealth Bank of Australia lifted its stake in Humana by 3.9% during the third quarter. Commonwealth Bank of Australia now owns 21,112 shares of the insurance provider’s stock worth $5,138,000 after purchasing an additional 796 shares during the last quarter. Prudential Financial Inc. lifted its stake in Humana by 53.6% during the third quarter. Prudential Financial Inc. now owns 378,133 shares of the insurance provider’s stock worth $92,125,000 after purchasing an additional 131,990 shares during the last quarter. Icon Advisers Inc. Co. lifted its stake in Humana by 22.7% during the third quarter. Icon Advisers Inc. Co. now owns 5,400 shares of the insurance provider’s stock worth $1,316,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its stake in Humana by 10.8% during the third quarter. Ameriprise Financial Inc. now owns 1,465,119 shares of the insurance provider’s stock worth $356,960,000 after purchasing an additional 142,706 shares during the last quarter. Institutional investors own 97.85% of the company’s stock.
Several brokerages recently issued reports on HUM. Zacks Investment Research cut Humana from a “buy” rating to a “hold” rating in a research note on Tuesday. JPMorgan Chase & Co. raised their price objective on Humana from $253.00 to $271.00 and gave the stock a “neutral” rating in a research note on Monday, February 12th. Oppenheimer raised their price objective on Humana from $275.00 to $305.00 and gave the stock an “outperform” rating in a research note on Thursday, February 8th. Cantor Fitzgerald restated a “hold” rating and set a $250.00 price objective on shares of Humana in a research note on Wednesday, February 7th. Finally, Leerink Swann raised their price objective on Humana from $280.00 to $300.00 and gave the stock an “outperform” rating in a research note on Thursday, February 8th. Eight research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $270.47.
Humana (NYSE:HUM) last issued its earnings results on Wednesday, February 7th. The insurance provider reported $2.06 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.00 by $0.06. The firm had revenue of $13.19 billion for the quarter, compared to analyst estimates of $13.14 billion. Humana had a return on equity of 16.13% and a net margin of 4.55%. The firm’s revenue for the quarter was up 2.4% on a year-over-year basis. During the same period last year, the company earned $2.34 earnings per share. equities analysts anticipate that Humana Inc will post 13.81 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, April 27th. Stockholders of record on Friday, March 30th will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.74%. This is a positive change from Humana’s previous quarterly dividend of $0.40. The ex-dividend date of this dividend is Wednesday, March 28th. Humana’s dividend payout ratio (DPR) is 9.59%.
Humana declared that its Board of Directors has approved a share repurchase plan on Thursday, December 14th that allows the company to buyback $3.00 billion in outstanding shares. This buyback authorization allows the insurance provider to purchase shares of its stock through open market purchases. Shares buyback plans are usually a sign that the company’s board believes its shares are undervalued.
In other news, SVP Cynthia H. Zipperle sold 1,196 shares of the firm’s stock in a transaction on Friday, March 9th. The stock was sold at an average price of $273.33, for a total transaction of $326,902.68. Following the transaction, the senior vice president now directly owns 7,771 shares of the company’s stock, valued at $2,124,047.43. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jody L. Bilney sold 7,054 shares of the firm’s stock in a transaction on Monday, December 18th. The shares were sold at an average price of $247.89, for a total value of $1,748,616.06. Following the transaction, the senior vice president now directly owns 11,704 shares in the company, valued at $2,901,304.56. The disclosure for this sale can be found here. Insiders have sold 41,775 shares of company stock worth $11,169,845 over the last three months. Corporate insiders own 0.60% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Humana Inc (HUM) Shares Sold by TIAA CREF Investment Management LLC” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2018/03/14/humana-inc-hum-shares-sold-by-tiaa-cref-investment-management-llc.html.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.